WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H318287
CAS#: 7416-34-4
Description: Molindone is a therapeutic antipsychotic, used in the treatment of schizophrenia. It works by blocking the effects of dopamine in the brain, leading to diminished psychoses. It is rapidly absorbed when taken orally.
Hodoodo Cat#: H318287
Name: Molindone
CAS#: 7416-34-4
Chemical Formula: C16H24N2O2
Exact Mass: 276.18
Molecular Weight: 276.374
Elemental Analysis: C, 69.53; H, 8.75; N, 10.14; O, 11.58
Synonym: Molindone, Moban, Molindonum
IUPAC/Chemical Name: 3-ethyl-2-methyl-5-(morpholin-4-ylmethyl)-1,5,6,7-tetrahydroindol-4-one
InChi Key: KLPWJLBORRMFGK-UHFFFAOYSA-N
InChi Code: InChI=1S/C16H24N2O2/c1-3-13-11(2)17-14-5-4-12(16(19)15(13)14)10-18-6-8-20-9-7-18/h12,17H,3-10H2,1-2H3
SMILES Code: O=C1C2=C(NC(C)=C2CC)CCC1CN3CCOCC3
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO, not in water
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
Biological target: | |
In vitro activity: | |
In vivo activity: |
The following data is based on the product molecular weight 276.37 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
Formulation protocol: | |
In vitro protocol: | |
In vivo protocol: |
1: McCue RE, Unuigbe FE, Charles RA, Orendain GC, Waheed R. Treatment of morbidly obese psychotic patients with molindone: three case reports. J Clin Psychiatry. 2009 Nov;70(11):1606-7. doi: 10.4088/JCP.09l05219yel. Review. PubMed PMID: 20031106.
2: Bagnall A, Fenton M, Lewis R, Leitner ML, Kleijnen J. Molindone for schizophrenia and severe mental illness. Cochrane Database Syst Rev. 2000;(2):CD002083. Review. Update in: Cochrane Database Syst Rev. 2007;(1):CD002083. PubMed PMID: 10796464.
3: Bagnall A, Fenton M, Kleijnen J, Lewis R. Molindone for schizophrenia and severe mental illness. Cochrane Database Syst Rev. 2007 Jan 24;(1):CD002083. Review. PubMed PMID: 17253473.
4: Owen RR Jr, Cole JO. Molindone hydrochloride: a review of laboratory and clinical findings. J Clin Psychopharmacol. 1989 Aug;9(4):268-76. Review. PubMed PMID: 2671060.
5: Ayd FJ Jr. A critical evaluation of molindone (Moban): a new indole derivative neuroleptic. Dis Nerv Syst. 1974 Oct;35(10):447-52. Review. PubMed PMID: 17894057.